1887
Volume 2005, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

In the early 1980s, patients with diabetic nephropathy (DN) had a doomed prognosis. Severe renal failure developed within five years of the onset of proteinuria.[1] The mortality was 53%, with 59% of deaths attributable to renal failure. There is no doubt that this devastating complication of diabetes has caused immeasurable human suffering and enormous healthcare costs.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2005.1.6
2005-06-01
2019-10-16
Loading full text...

Full text loading...

References

  1. 1. Kussman   MJ., , Goldstein   HH., , Gleason   RE. . The clinical course of diabetic nephropathy. . JAMA . 1976; ;236: 16 : 1861– 1863 .
    [Google Scholar]
  2. 2. Burns   KD. . Angiotensin II and its receptors in the diabetic kidney. . Am J Kidney Dis . 2000; ;36: 3 : 449– 467 .
    [Google Scholar]
  3. 3. Miller   JA. . Impact of hyperglycemia on the renin angiotensin system in early human type-1 diabetes mellitus. . J Am Soc Nephrol . 1999; ;10: : 1778– 1785 .
    [Google Scholar]
  4. 4. Mizuiri   S., , Yoshikawa   H., , Tanegashima   M., , Miyagi   M., , Kobayashi   M., , Sakai   K., , Hayashi   I., , Aikawa   A., , Ohara   T., , Hasegawa   A. . Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. . Am J Kidney Dis . 1998; ;31: : 301– 307 .
    [Google Scholar]
  5. 5. Hollenberg   NK., , Fisher   ND., , Price   DA. . Pathways for angiotensin II generation in intact human tissue evidence from comparative pharmacological interruption of the rennin system. . Hypertension . 1998; ;32: : 387– 392 .
    [Google Scholar]
  6. 6. Hollenberg   NK. . Implications of species differences for clinical investigation: studies on the rennin angiotensin system. . Hypertension . 2000; ;35: : 150– 154 .
    [Google Scholar]
  7. 7. Ritz   E. . Chymase: a potential culprit in diabetic nephropathy?.   J Am Soc Nephrol . 2003; ;14: : 1952– 1954 .
    [Google Scholar]
  8. 8. Ruggenenti   P., , Mosconi   L., , Sangalli   F., , Casiraghi   F., , Gambara   V., , Remuzzi   G., , Remuzzi   A. . Glomerular size selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. . Kidney Int . 1999; ;55: : 984– 994 .
    [Google Scholar]
  9. 9. Zatz   R., , Dunn   BR., , Meyer   TW., , Anderson   S., , Rennke   HG., , Brenner   BM. . Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. . J Clin Invest . 1986; ;77: : 1925– 1930 .
    [Google Scholar]
  10. 10. Lewis   EJ., , Hunsicker   LG., , Bain   RP., , Rohde   RD., , for the Collaborative study group. . The effect of Angiotensinconverting-enzyme inhibition on diabetic nephropathy. . N Engl J Med . 1993; ;329: : 1456– 1462 .
    [Google Scholar]
  11. 11. Lewis   EJ., , Hunsicker   LG., , Clarke   WR., , Berl   T., , Pohl   MA., , Lewis   JB., , Ritz   E., , Atkins   RC., , Rohde   R., , Raz   I., , for the Collaborative study group. . Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type-2 diabetes. . N Engl J Med . 2001; ;345: : 851– 860 .
    [Google Scholar]
  12. 12. Brenner   BM., , Cooper   ME., , Zeeuw   DD., , Keane   WF., , Mitch   WE., , Parving   HH., , Remuzzi   G., , Snappin   SM., , Zhang   Z., , Shahinfar   S. . for the RENAAL study investigators. Effects of Losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. . N Engl J Med . 2001; ;345: : 861– 869 .
    [Google Scholar]
  13. 13. Strippoli   GFM., , Craig   M., , Schena   FP., , Craig   JC. . Improved survival with ACE inhibitors compared with angiotensin II receptor antagonists in patients with diabetic nephropathy. . J Am Soc Nephrol . 2003; ;14: : 6A .
    [Google Scholar]
  14. 14. Heart Outcomes Prevention Evaluation study investigators . The effect of Ramipril on cardiovascular and micro vascular outcomes in people with diabetes mellitus: result of the HOPE study and the MICRO-HOPE sub study. . Lancet . 2000; ;355: : 253– 259 .
    [Google Scholar]
  15. 15. Pfeffer   MA., , McMurray   JJ., , Velazquez   EJ., , Rouleau   JL., , Kober   L., , Maggioni   AP., , Solomon   SD., , Swedberg   K., , Van de Werf   F., , White   H., , Leimberger   JD., , Henis   M., , Edwards   S., , Zelenkofske   S., , Sellars   MA., , Califf   RM., , for the Valsartan in Acute Myocardial Infarction trial investigators. . Valsartan, Captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. . N Engl J Med . 2003; ;349: : 1893– 1906 .
    [Google Scholar]
  16. 16. McMurray   JJ., , Ostergren   J., , Swedberg   K., , Granger   CB., , Held   P., , Mychelson   EL., , Oloffson   B., , Yusuf   S., , Pfeffer   MA., , for the CHARM investigators and committees. . Effects of Candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: The CHARM-Added trial. . Lancet . 2003; ;362: : 767– 771 .
    [Google Scholar]
  17. 17. Lindholm   LH., , Ibsen   H., , Dahlof   B., , Devereux   B., , Beevers   G., , deFaire   U., , Fyhrquist   F., , Julis   S., , Kjeldsen   SE., , Kristiansson   K., , Lederballe-Pedersen   O., , Nieminen   MS., , Omvik   T., , Oparil   S., , Wedel   H., , Aurup   T., , Edelman   J., , Snapinn   S., , for the LIFE study group. . Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against Atenolol. . Lancet . 2002; ;359: : 1004– 1010 .
    [Google Scholar]
  18. 18. Parving   HH., , Lenhert   H., , Brochner-Mortenson   J., , Gomis   R., , Andersen   S., , Arner   P., , for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. . The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. . N Engl J Med . 2001; ;345: : 870– 878 .
    [Google Scholar]
  19. 19. Panos   J., , Michelis   MF., , DeVita   MV., , Lavie   RH., , Wilkes   BM. . Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism. . Clinical Nephrology . 2003; ;60: 1 : 13– 21 .
    [Google Scholar]
  20. 20. Mogensen   CE., , Neldam   S., , Tikkanen   I., , Oren   S., , Viskoper   R., , Watts   RW., , Cooper   ME. . Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. . BMJ . 2000; ;321: 7274 : 1440– 1444 .
    [Google Scholar]
  21. 21. Jacob sen   P., , Andersen   S., , Jensen   BR., , Parving   HH. . Additive effect of ACE inhibition and angiotensin II receptor blockade in type-1 diabetic patients with diabetic nephropathy. . J Am Soc Nephrol . 2003; ;14: : 992– 999 .
    [Google Scholar]
  22. 22. Jacobsen   P., , Andersen   S., , Rossing   K., , Jensen   BR., , Parving   HH. . Dual blockade of the rennin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. . Kidney Int . 2003; ;63: : 1874– 1880 .
    [Google Scholar]
  23. 23. Smith   PK., , Fairley   KF., , Packham   D. . Dual blockade of the rennin-angiotensin system compared with a 50% increase in the dose of angiotensin -converting enzyme inhibitor: effects on proteinuria and blood pressure. . Nephrol Dial Transplant . 2004; ;19: 9 : 2272– 2274 .
    [Google Scholar]
  24. 24. Mau Pedersen   M., , Schmitz   A., , Pedersen   EB., , Danielsen   H., , Christiansen   JS. . Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. . Diabetic Med . 1988; ;5: : 562– 569 .
    [Google Scholar]
  25. 25. Schrier   RW., , Estacio   RO., , Esler   A., , Mehler   P. . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. . Kidney Int . 2002; ;61: : 1086– 1097 .
    [Google Scholar]
  26. 26. Diabetes control and complications Trial research group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in Insulin-dependentdiabetes mellitus. . N Engl J Med . 1993; ;329: : 977– 986 .
    [Google Scholar]
  27. 27. UK Prospective Diabetes Study (UKPDS) group . Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). . Lancet . 1998; ;352: : 837– 853 .
    [Google Scholar]
  28. 28. Schrier   RW., , Estacio   RO., , Esler   A., , Mehler   P. . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. . Kidney Int . 2002; ;61: : 1086– 1097 .
    [Google Scholar]
  29. 29. Gaede   P., , Vadel   P., , Parving   HH., , Pedersen   O. . Intensified multifactorial intervention in patients with type-2 diabetes mellitus and microalbuminuria: Steno type 2 randomized study. . Lancet . 1999; ;353: : 617– 622 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2005.1.6
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error